A Phase II Trial of CyberKnife Radiosurgery to Perioptic Tumors
NCT ID: NCT02225197
Last Updated: 2019-07-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
10 participants
INTERVENTIONAL
2007-12-31
2017-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators hypothesize that hypofractionated stereotactic radiotherapy via the CyberKnife ® can deliver tumor ablating doses of radiation to perioptic lesions safely and effectively while sparing the adjacent optic apparatus and normal brain tissues from receiving damaging doses of radiation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trail Evaluating Carbon Ion Radiotherapy (3 GyE Per Fraction) for Locally Recurrent Nasopharyngeal Carcinoma
NCT02795195
Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
NCT00852644
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
NCT01890590
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
NCT02701153
Extracranial Stereotactic Radiosurgery in Treating Patients With Solid Tumors
NCT00311597
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CyberKnife Radiosurgery
CyberKnife Radiosurgery
25 Gy delivered in 5 fractions of 5 Gy per fraction
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CyberKnife Radiosurgery
25 Gy delivered in 5 fractions of 5 Gy per fraction
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \>= 21
* KPS \>= 50
* Planning Target Volume (PTV) \<= 6.0 cm in maximal diameter
Exclusion Criteria
* Age \< 21
* KPS \<= 40
* Planning Target Volume (PTV) \> 6.0 cm in maximal diameter
* Prior whole brain XRT
* Gross total resection
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Community Cancer Center, Normal, Illinois
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shermian Woodhouse, MD
Role: PRINCIPAL_INVESTIGATOR
Community Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Community Cancer Center
Normal, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CK Perioptic-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.